References
- Zhu Z, Li J, Ruan G, Wang G, Huang C, Ding C. Investigational drugs for the treatment of osteoarthritis, an update on recent developments. Expert Opin Investig Drugs. 2018;27(11):881–900. doi:10.1080/13543784.2018.1539075
- Dell’Isola A, Allan R, Smith SL, Marreiros SS, Steultjens M. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord. 2016;17(1):425. doi:10.1186/s12891-016-1286-2
- Fu M, Zhou H, Li Y, Jin H, Liu X. Global, regional, and national burdens of Hip osteoarthritis from 1990 to 2019: estimates from the 2019 Global Burden of Disease Study. Arthritis Res Ther. 2022;24(1):8. doi:10.1186/s13075-021-02705-6
- Evans JT, Walker RW, Evans JP, Blom AW, Sayers A, Whitehouse MR. How long does a knee replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up. Lancet. 2019;393(10172):655–663. doi:10.1016/S0140-6736(18)32531-5
- Louati K, Vidal C, Berenbaum F, Sellam J. Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. RMD Open. 2015;1(1):e000077. doi:10.1136/rmdopen-2015-000077
- Centers for Disease C, Prevention. Arthritis as a potential barrier to physical activity among adults with diabetes--United States, 2005 and 2007. MMWR Morb Mortal Wkly Rep. 2008;57(18):486–489.
- Chen S, Ruan G, Zeng M, et al. Association between metformin use and risk of total knee arthroplasty and degree of knee pain in knee osteoarthritis patients with diabetes and/or obesity: a retrospective study. J Clin Med. 2022;11(16):4796.
- Lai FTT, Yip BHK, Hunter DJ, et al. Metformin use and the risk of total knee replacement among diabetic patients: a propensity-score-matched retrospective cohort study. Sci Rep. 2022;12(1):11571. doi:10.1038/s41598-022-15871-7
- Zhu Z, Huang JY, Ruan G, et al. Metformin use and associated risk of total joint replacement in patients with type 2 diabetes: a population-based matched cohort study. CMAJ. 2022;194(49):E1672–E1684. doi:10.1503/cmaj.220952
- Piva SR, Susko AM, Khoja SS, Josbeno DA, Fitzgerald GK, Toledo FG. Links between osteoarthritis and diabetes: implications for management from a physical activity perspective. Clin Geriatr Med. 2015;31(1):67–87, viii. doi:10.1016/j.cger.2014.08.019
- Zhang C, Chen S, Li Q, et al. Ultrasound-Targeted Microbubble Destruction Mediates Gene Transfection for Beta-Cell Regeneration and Glucose Regulation. Small. 2021;17(31):e2008177. doi:10.1002/smll.202008177
- Xie F, Li R, Shu W, Zhao L, Wan J. Self-assembly of Peptide dendrimers and their bio-applications in theranostics. Mater Today Bio. 2022;14:100239. doi:10.1016/j.mtbio.2022.100239
- Liu S, Xu J, Xing Y, et al. Nanozymes as efficient tools for catalytic therapeutics. View. 2021;3(2):20200147. doi:10.1002/VIW.20200147
- Zhong D, Du Z, Zhou M. Algae: a natural active material for biomedical applications. VIEW. 2021;2(4):20200189. doi:10.1002/VIW.20200189
- Courties A, Sellam J. Osteoarthritis and type 2 diabetes mellitus: what are the links? Diabetes Res Clin Pract. 2016;122:198–206. doi:10.1016/j.diabres.2016.10.021
- Veronese N, Cooper C, Reginster JY, et al. Type 2 diabetes mellitus and osteoarthritis. Semin Arthritis Rheum. 2019;49(1):9–19. doi:10.1016/j.semarthrit.2019.01.005
- Park MJ, Moon SJ, Baek JA, et al. Metformin augments anti-inflammatory and chondroprotective properties of mesenchymal stem cells in experimental osteoarthritis. J Immunol. 2019;203(1):127–136. doi:10.4049/jimmunol.1800006
- Bandow K, Kusuyama J, Kakimoto K, Ohnishi T, Matsuguchi T. AMP-activated protein kinase (AMPK) activity negatively regulates chondrogenic differentiation. Bone. 2015;74:125–133. doi:10.1016/j.bone.2014.12.001
- Kuusalo L, Felson DT, Wang N, et al. Metabolic osteoarthritis - relation of diabetes and cardiovascular disease with knee osteoarthritis. Osteoarthritis Cartilage. 2021;29(2):230–234. doi:10.1016/j.joca.2020.09.010